MCID: ART140
MIFTS: 66

Arteries, Anomalies of

Categories: Cardiovascular diseases

Aliases & Classifications for Arteries, Anomalies of

MalaCards integrated aliases for Arteries, Anomalies of:

Name: Arteries, Anomalies of 58
Artery Disease 12 15
Arteriopathic Disease 74

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
arteries, anomalies of:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0050828
OMIM 58 108000
MedGen 43 C1876179
SNOMED-CT via HPO 70 263681008 49601007
UMLS 74 C0852949

Summaries for Arteries, Anomalies of

Disease Ontology : 12 A vascular disease that is located in an artery.

MalaCards based summary : Arteries, Anomalies of, also known as artery disease, is related to peripheral artery disease and carotid artery disease. An important gene associated with Arteries, Anomalies of is REN (Renin), and among its related pathways/superpathways are Vesicle-mediated transport and p70S6K Signaling. The drugs Aspirin and AT-101 have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and testes, and related phenotypes are abnormality of the cardiovascular system and Decreased free cholesterol

Description from OMIM: 108000

Related Diseases for Arteries, Anomalies of

Diseases related to Arteries, Anomalies of via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 711)
# Related Disease Score Top Affiliating Genes
1 peripheral artery disease 34.5 ACE APOB CRP IL6 NOS3 VCAM1
2 carotid artery disease 34.4 ACE APOA1 APOB APOE COG2 CRP
3 renal artery disease 34.1 ACE AGT AGTR1 NOS3 REN
4 pulmonary artery disease 34.0 ALB PLAT PLG TNNI3
5 coronary artery anomaly 33.8 ACE AGTR1 APOA1 APOB COG2 CRP
6 peripheral vascular disease 33.8 ACE ALB APOA1 APOB CRP IL6
7 hyperlipoproteinemia, type iii 33.4 APOA1 APOB APOE COG2 LPA
8 hypercholesterolemia, familial 33.1 ACE AGT APOA1 APOB APOE COG2
9 coronary heart disease 1 33.0 ACE APOA1 APOB APOE COG2 CRP
10 atherosclerosis susceptibility 32.9 APOA1 APOB APOE CRP IL6 INS
11 angina pectoris 32.6 ACE CRP EDN1 IL6 NOS3 PLAT
12 stroke, ischemic 32.6 ACE AGTR1 APOB APOE COG2 CRP
13 hyperlipidemia, familial combined 32.5 APOA1 APOB COG2 LPA
14 aortic disease 32.5 APOE CRP IL6 REN
15 fibromuscular dysplasia 32.5 ACE AGT AGTR1 REN
16 tangier disease 32.5 APOA1 APOB APOE LPA
17 pulmonary embolism 32.5 ALB CRP PLAT TNNI3
18 arteriosclerosis 32.3 ACE APOA1 APOB APOE COG2 CRP
19 hypercholesterolemia, autosomal dominant, type b 32.2 APOB APOE
20 vascular disease 32.1 ACE ALB APOA1 APOB APOE CRP
21 hypertension, essential 32.1 ACE AGT AGTR1 ALB APOA1 APOB
22 myocardial infarction 32.1 ACE AGT AGTR1 ALB APOA1 APOB
23 ischemia 31.9 ACE EDN1 NOS3 PLAT
24 intermittent claudication 31.4 ACE ALB CRP IL6
25 limb ischemia 31.4 ACE EDN1 IL6 NOS3 TNNI3
26 atrial fibrillation 31.3 ACE AGT AGTR1 CRP PLAT
27 diabetes mellitus 31.2 ACE AGT AGTR1 ALB APOA1 APOB
28 congestive heart failure 31.2 ACE AGTR1 EDN1 REN
29 carotid stenosis 31.2 ACE APOE CRP
30 coronary stenosis 31.1 ACE ALB APOA1 APOB APOE CRP
31 acute myocardial infarction 31.1 ACE AGTR1 APOA1 APOB CRP EDN1
32 aortic valve disease 2 31.1 ACE AGT CRP REN
33 heart valve disease 31.0 ACE CRP REN
34 hypertriglyceridemia, familial 31.0 APOA1 APOB APOE INS
35 kidney disease 31.0 ACE AGT AGTR1 ALB APOE CRP
36 orthostatic intolerance 31.0 AGTR1 EDN1 NOS3
37 sleep apnea 31.0 ACE APOE CRP EDN1 IL6 INS
38 kawasaki disease 30.9 ALB CRP IL6
39 lipid metabolism disorder 30.9 ACE APOA1 APOB APOE COG2 CRP
40 heart disease 30.9 ACE AGTR1 ALB APOA1 APOB APOE
41 ischemic heart disease 30.9 ACE AGTR1 APOA1 APOB APOE CRP
42 systolic heart failure 30.9 ACE CRP EDN1 IL6
43 homocysteinemia 30.9 ALB CRP NOS3
44 end stage renal failure 30.8 ACE AGT AGTR1 ALB APOB CRP
45 chronic kidney failure 30.8 ACE AGT AGTR1 ALB APOB CRP
46 aortic coarctation 30.8 ACE AGT AGTR1 EDN1 NOS3
47 aortic atherosclerosis 30.8 ACE APOE LPA
48 hyperuricemia 30.8 APOB CRP INS REN
49 cerebrovascular disease 30.8 ACE AGTR1 APOA1 APOB APOE CRP
50 microvascular complications of diabetes 3 30.7 ACE AGT AGTR1 ALB INS

Graphical network of the top 20 diseases related to Arteries, Anomalies of:



Diseases related to Arteries, Anomalies of

Symptoms & Phenotypes for Arteries, Anomalies of

Human phenotypes related to Arteries, Anomalies of:

33
# Description HPO Frequency HPO Source Accession
1 abnormality of the cardiovascular system 33 HP:0001626

Symptoms via clinical synopsis from OMIM:

58
Vascular:
abnormal radial, ulnar, or interosseous artery

Clinical features from OMIM:

108000

GenomeRNAi Phenotypes related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.92 APOA1 APOB APOE LPA

MGI Mouse Phenotypes related to Arteries, Anomalies of:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.43 ACE AGT AGTR1 APOA1 APOB APOE
2 homeostasis/metabolism MP:0005376 10.36 ACE AGT AGTR1 ALB APOA1 APOB
3 growth/size/body region MP:0005378 10.32 ACE AGT AGTR1 APOB APOE COG2
4 immune system MP:0005387 10.22 ACE AGT AGTR1 APOB APOE CRP
5 hematopoietic system MP:0005397 10.2 ACE AGTR1 APOE COG2 IL6 INS
6 mortality/aging MP:0010768 10.2 ACE AGT AGTR1 ALB APOB APOE
7 endocrine/exocrine gland MP:0005379 10.19 ACE ALB APOA1 APOE EDN1 IL6
8 digestive/alimentary MP:0005381 10.11 ALB APOE EDN1 IL6 INS NOS3
9 adipose tissue MP:0005375 10.08 ACE AGT AGTR1 APOE IL6 INS
10 liver/biliary system MP:0005370 10.07 ACE AGT ALB APOA1 APOB APOE
11 muscle MP:0005369 10 AGT ALB APOB APOE EDN1 IL6
12 nervous system MP:0003631 9.9 AGT AGTR1 APOB APOE EDN1 IL6
13 renal/urinary system MP:0005367 9.7 ACE AGT AGTR1 ALB APOE EDN1
14 reproductive system MP:0005389 9.36 ACE AGT APOB APOE IL6 INS

Drugs & Therapeutics for Arteries, Anomalies of

Drugs for Arteries, Anomalies of (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1041)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
2
AT-101 Approved, Investigational Phase 4,Phase 3,Not Applicable 90141-22-3, 652-67-5 12597
3
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 134523-00-5 60823
4
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10102-43-9 145068
5
Clopidogrel Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 120202-66-6, 113665-84-2 60606
6
Isosorbide Dinitrate Approved, Investigational Phase 4,Phase 3,Not Applicable 87-33-2 6883
7
Metoprolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 37350-58-6, 51384-51-1 4171
8
Trimetazidine Approved, Investigational Phase 4,Phase 2,Not Applicable 5011-34-7
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
10
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 5284616 6436030
11
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 159351-69-6 70789204 6442177
12
Ticagrelor Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 274693-27-5 9871419
13
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 73963-72-1 2754
14
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 46507594 772
15
Tirofiban Approved Phase 4,Phase 3,Phase 1 144494-65-5 60947
16 Nutmeg Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55-56-1 2713 9552079
18
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 79902-63-9 54454
19
Insulin glargine Approved Phase 4,Phase 3,Not Applicable 160337-95-1
20
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
21
Zinc Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable,Early Phase 1 7440-66-6 32051
22
Amlodipine Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 88150-42-9 2162
23
Warfarin Approved Phase 4,Phase 3,Not Applicable 81-81-2 54678486 6691
24
Rivaroxaban Approved Phase 4,Phase 3,Phase 2 366789-02-8
25
Ranolazine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 95635-55-5, 142387-99-3 56959
26
Nicotinamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 98-92-0 936
27
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
28
Cobalt Approved, Experimental Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-48-4 104729
29
Chromium Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 7440-47-3 27668
30
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 122320-73-4 77999
31
Pitavastatin Approved Phase 4,Phase 3,Not Applicable 147511-69-1, 147526-32-7 5282452 6366718
32
Ezetimibe Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 163222-33-1 150311
33
Lovastatin Approved, Investigational Phase 4,Phase 2,Phase 3 75330-75-5 53232
34
Acarbose Approved, Investigational Phase 4,Phase 3,Not Applicable 56180-94-0 441184
35
Bivalirudin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 128270-60-0 16129704
36
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1406-66-2 14986
37
Thrombin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable
38
Vorapaxar Approved Phase 4,Phase 3,Phase 2 618385-01-6
39
Regadenoson Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 313348-27-5 219024
40
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-61-7 60961
41
Dipyridamole Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-32-2 3108
42
Pantoprazole Approved Phase 4,Phase 3,Not Applicable 102625-70-7 4679
43
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3 73590-58-6 4594
44
Fenoldopam Approved Phase 4 67227-56-9, 67227-57-0 3341
45
Dopamine Approved Phase 4,Phase 2,Phase 3,Not Applicable 62-31-7, 51-61-6 681
46
Coal tar Approved Phase 4,Phase 1,Phase 2 8007-45-2
47
Eptifibatide Approved, Investigational Phase 4,Phase 3,Phase 2 188627-80-7 123610
48
Nicorandil Approved, Investigational Phase 4,Not Applicable 65141-46-0 47528
49
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
50
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337

Interventional clinical trials:

(show top 50) (show all 6968)
# Name Status NCT ID Phase Drugs
1 Curative Effect Evaluation of Danlou Tablet on Coronary Artery Disease Not Amenable to Revascularization Unknown status NCT03072082 Phase 4 Danlou Tablet;DanLou Tablet placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
2 Curative Effect Evaluation of Shexiang Baoxin Pill on Coronary Artery Disease Not Amenable to Revascularization Unknown status NCT03072121 Phase 4 Shexiang Baoxin pill;SBP placebo;Aspirin Enteric-coated Tablets;Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet;Atorvastatin Calcium;Isosorbide Mononitrate Tab 20 MG;Metoprolol Tartrate Tab 25 MG;Trimetazidine Dihydrochloride Tablets
3 The Beneficial Role of Percutaneous Coronary Intervention Over Optimal Medical Therapy in Elderly Patients With Coronary Artery Disease Unknown status NCT01508663 Phase 4 ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.
4 Safety and Efficacy of Low-dose Ticagrelor in Chinese Patients With Stable Coronary Artery Disease Unknown status NCT02514642 Phase 4 low-dose ticagrelor;Clopidogrel
5 A Trial to Evaluate Efficacy of Heart-protecting Musk Pill Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
6 Far Infrared Therapy on Peripheral Artery Disease in Hemodialysis Patients Unknown status NCT01095549 Phase 4
7 Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease Unknown status NCT02174939 Phase 4 Cilostazol;Dummy Placebo
8 Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease Unknown status NCT02294994 Phase 4 tirofiban
9 The Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
10 Firebird 2 Versus Excel Sirolimus-eluting Stent in Treating Real-world Patients With Coronary Artery Disease Unknown status NCT01373632 Phase 4
11 Pharmacodynamic Comparison of Rosuvastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With New P2Y12 Inhibitors (Trial gRANADa) Unknown status NCT02030054 Phase 4 Atorvastatin;Rosuvastatin
12 Low-dose Statins and Nutraceuticals in High-intensity Statin-intolerant Patients Unknown status NCT02001883 Phase 4 Association low-dose statin and nutraceuticals
13 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM) Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
14 The ImPact of Trimetazidine on MicrOcirculation After Stenting for Stable Coronary Artery Disease Unknown status NCT02107144 Phase 4 trimetazidine
15 Can Insulin Glargine Improve Myocardial Function in Patients With T2D and Coronary Artery Disease (CAD) Unknown status NCT01035528 Phase 4 insulin glargine;metformin
16 Residual Platelet Activity In Advanced Peripheral Artery Disease Unknown status NCT01627431 Phase 4 Acetylsalicylic acid;Clopidogrel
17 Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia Unknown status NCT00247533 Phase 4
18 Xience/Promus for Long Coronary Lesion Registry Unknown status NCT01147237 Phase 4
19 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer SES Safety and Effectiveness in CAD Treatment Unknown status NCT01880879 Phase 4
20 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on Platelet Reactivity Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
21 Comparison of Biomatrix and Orsiro Drug Eluting Stent Unknown status NCT02299011 Phase 4 Biomatrix drug eluting stent
22 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
23 Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity Unknown status NCT01490255 Phase 4 Ranolazine;Amlodipine
24 Effects of Nicotinic Acid Plus Simvastatin Versus Simvastatin Alone on Carotid and Femoral Intima-Media Thickness in Patients With Peripheral Artery Disease (NASCIT) Unknown status NCT00712049 Phase 4 simvastatin;Nicotinic Acid
25 Efficacy Study of Stenting, Paclitaxel Eluting Balloon or Atherectomy to Treat Peripheral Artery Disease Unknown status NCT00986752 Phase 4
26 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
27 Safety and Effectiveness of the Coronary Momo Stent Unknown status NCT01535625 Phase 4
28 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
29 Ranolazine, Ethnicity and the Metabolic Syndrome Unknown status NCT01304095 Phase 4 Ranolazine
30 Efficacy of Self-Expanding Nitinol S.M.A.R.T CONTROL Stent Versus Life Stent For The Atherosclerotic Femoro-Popliteal Arterial Disease Unknown status NCT01653600 Phase 4
31 Assessment of Surface Coverage of Two Types of DES in Diabetes Mellitus and Non- Diabetes Mellitus Unknown status NCT01023919 Phase 4
32 Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor Unknown status NCT01869309 Phase 4 Prasugrel;Ticagrelor
33 Endothelial Dysfunction in Subjects With History of Premature Coronary Artery Disease Unknown status NCT00917527 Phase 4 Atorvastatin
34 Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI Unknown status NCT01781715 Phase 4
35 Rosiglitazone Therapy In The Prevention Of Coronary Artery Disease In Patients With Impaired Glucose Tolerance Unknown status NCT00733174 Phase 4 Rosiglitazone;Placebo
36 Walking Estimated Limitation Calculated by History - Study 2 Unknown status NCT01424020 Phase 4
37 PharmacOdynamic compaRison of piTavastatin Versus atOrvastatin on Platelet Reactivity Unknown status NCT01648829 Phase 4 Atorvastatin;Pitavastatin
38 A Multicenter, Therapeutic Used Study to Evaluate the Efficacy and Safety of Pletaal SR Capsule (Cilostazol) in Subjects With Peripheral Arterial Disease Symptom Due to Chronic Occlusive Arterial Disease Unknown status NCT01711333 Phase 4 Pletaal SR capsule
39 Cholesterol-lowering Effects of nutraceuticaLs Versus Ezetimibe in Statin-intolerant Patients Unknown status NCT01807078 Phase 4 Ezetimibe
40 Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial) Unknown status NCT00858676 Phase 4 acarbose
41 Platelets Induced Vasodilation, in Vitro and in Vivo Study Unknown status NCT00152646 Phase 4 placebo, aspirine, clopidogrel
42 Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents Unknown status NCT02894255 Phase 4
43 Periodontal Therapy in Coronary Artery Patients Unknown status NCT01609725 Phase 4
44 Plasma and Platelet microRNAs in Clopidogrel Low Response Patients Unknown status NCT02447809 Phase 4 Clopidogrel;acetylsalicylic acid (ASA)
45 Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents Unknown status NCT01268371 Phase 4
46 A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization Unknown status NCT01157455 Phase 4 Aspirin;Clopidogrel;Heparin or Bivalirudin
47 Italian Diffuse/Multivessel Disease ABSORB Prospective Registry: IT-Disappears Unknown status NCT02004730 Phase 4
48 The Effects of Omega 3 and Vitamin E Supplementation on the Serum Antioxidant Enzymes and Gene Expressions of PGC-1a, h TERT, FOXOs and SIRTs in CAD Patients Unknown status NCT02011906 Phase 4
49 Diagnostic Performance of Noninvasive Fractional Flow Reserve From Computed Tomography Unknown status NCT01747317 Phase 4
50 Comparison of the Everolimus Eluting With the Biolimus A9 Eluting Stent Unknown status NCT01233453 Phase 4

Search NIH Clinical Center for Arteries, Anomalies of

Genetic Tests for Arteries, Anomalies of

Anatomical Context for Arteries, Anomalies of

MalaCards organs/tissues related to Arteries, Anomalies of:

42
Heart, Endothelial, Testes, Kidney, Bone, Brain, Bone Marrow

The Foundational Model of Anatomy Ontology organs/tissues related to Arteries, Anomalies of:

20
An Artery

Publications for Arteries, Anomalies of

Articles related to Arteries, Anomalies of:

(show top 50) (show all 10172)
# Title Authors Year
1
Clinical Significance of Platelet Volume and Other Platelet Parameters in Acute Myocardial Infarction and Stable Coronary Artery Disease. ( 30942294 )
2019
2
Glycaemic variability is associated with severity of coronary artery disease in patients with poorly controlled type 2 diabetes and acute myocardial infarction. ( 30763700 )
2019
3
Treatment of Coronary Artery Disease and Acute Myocardial Infarction in Hospitals With and Without On-Site Coronary Artery Bypass Graft Surgery. ( 30616362 )
2019
4
Free IGF-1, Intact IGFBP-4, and PicoPAPP-A are Altered in Acute Myocardial Infarction Compared to Stable Coronary Artery Disease and Healthy Controls. ( 30497090 )
2019
5
Urinary excretion of homocysteine thiolactone and the risk of acute myocardial infarction in coronary artery disease patients: the WENBIT trial. ( 30193001 )
2019
6
Vaginitis, Coronary Artery Disease, Hypertension in Children, COPD, Alzheimer Disease. ( 31038905 )
2019
7
CPC Commentary on "Coexistence of cardiac amyloidosis with coronary artery disease and the challenges in medical management". ( 30989493 )
2019
8
The Effect of Two Methods of Relaxation and Prayer Therapy on Anxiety and Hope in Patients with Coronary Artery Disease: A Quasi-Experimental Study. ( 30820220 )
2019
9
Rheumatoid arthritis patients have higher prevalence and burden of asymptomatic coronary artery disease assessed by coronary computed tomography: A systematic literature review and meta-analysis. ( 30826172 )
2019
10
Thromboembolic Risk of Imaging-Confirmed Coronary Artery Disease Without Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation. ( 30709601 )
2019
11
Radiofrequency catheter ablation prior to percutaneous coronary intervention in patients with atrial fibrillation coexisting with stable coronary artery disease: a single-center pilot study. ( 30324245 )
2019
12
Carotid Artery Disease in Post-Stroke Survivors and Effects of Enriched Environment on Stroke Pathology in a Mouse Model of Carotid Artery Stenosis. ( 30947376 )
2019
13
Recent advances in the treatment of carotid artery disease. ( 30845790 )
2019
14
Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. ( 30703812 )
2019
15
Nonlinear model for the carotid artery disease 10-year risk prediction by fusing conventional cardiovascular factors to carotid ultrasound image phenotypes: A Japanese diabetes cohort study. ( 30623485 )
2019
16
Intracerebral steal phenomenon in symptomatic carotid artery disease. ( 30389512 )
2019
17
Snoring and carotid artery disease: A new risk factor emerges. ( 30194704 )
2019
18
Anti-ApoA-I IgG antibodies are not associated with carotid artery disease progression and first-time cardiovascular events in middle-aged individuals. ( 30028049 )
2019
19
Angiographic characteristics and long-term prognostic impact of coronary artery disease in survivors after sudden cardiac arrest with a non-diagnostic electrocardiogram. ( 30280478 )
2019
20
Burden of Coronary Artery Disease as a Cause of Sudden Cardiac Arrest in the Young. ( 31023437 )
2019
21
Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48. ( 30039978 )
2019
22
Cardiovascular outcomes among elderly patients with heart failure and coronary artery disease and without atrial fibrillation: a retrospective cohort study. ( 30646855 )
2019
23
Double Jeopardy: Will the new trials tell us how to manage patients with atrial fibrillation and coronary artery disease? ( 31111088 )
2019
24
Associations between statins and coronary artery disease and stroke risks in patients with asthma-chronic obstructive pulmonary disease overlap syndrome: A time-dependent regression study. ( 30782562 )
2019
25
Subclinical coronary artery disease in recent-onset of rheumatoid arthritis. ( 30723868 )
2019
26
The effect of Xinkeshu tablets on depression and anxiety symptoms in patients with coronary artery disease: Results from a double-blind, randomized, placebo-controlled study. ( 30784924 )
2019
27
Effect of Sexual Rehabilitation Program on Anxiety, Stress, Depression and Sexual Function among Men with Coronary Artery Disease. ( 30912471 )
2019
28
Relationship between major depressive disorder, generalized anxiety disorder and coronary artery disease in the US general population. ( 30947822 )
2019
29
Using path analysis to investigate the relationships between depression, anxiety, and health-related quality of life among patients with coronary artery disease. ( 31098799 )
2019
30
3D-speckle tracking echocardiography for assessment of coronary artery disease severity in stable angina pectoris. ( 30515893 )
2019
31
Coexistence of cardiac amyloidosis with coronary artery disease and the challenges in medical management. ( 30788761 )
2019
32
Potential associations of testosterone/estradiol ratio, leukocyte hTERT expression and PBMC telomerase activity with aging and the presence of coronary artery disease in men. ( 30179663 )
2019
33
Age-dependent association of pulse wave velocity with coronary artery disease and myocardial aging in high-risk patients. ( 30676495 )
2019
34
Low CPNE3 expression is associated with risk of acute myocardial infarction: A feasible genetic marker of acute myocardial infarction in patients with stable coronary artery disease. ( 29297177 )
2019
35
Multiple Coronary Artery Bypass Grafting for Kawasaki Disease-Associated Coronary Artery Disease. ( 31039352 )
2019
36
Association Of Hypertensive Retinopathy With Angiographic Severity Of Coronary Artery Disease Determined By Syntax Score. ( 31094114 )
2019
37
Where are we with coronary artery disease for the cyanotic patient with congenital heart disease? ( 30665555 )
2019
38
Targeted Sequencing Study to Uncover Shared Genetic Susceptibility Between Peripheral Artery Disease and Coronary Heart Disease. ( 31070467 )
2019
39
Value of Cardiogoniometry in Diagnosis of Coronary Artery Disease in Patients with Suspected Stable Ischemic Heart Disease. ( 31105147 )
2019
40
Increased ischemic stroke, acute coronary artery disease and mortality in patients with granulomatosis with polyangiitis and microscopic polyangiitis. ( 30236485 )
2019
41
Hepatitis C virus infection and risk of coronary artery disease: A meta-analysis. ( 31006509 )
2019
42
Durability of Benefits From Supervised Treadmill Exercise in People With Peripheral Artery Disease. ( 30587066 )
2019
43
Clinical Outcomes and Cost Comparisons of Stent and Non-Stent Interventions in Infrainguinal Peripheral Artery Disease: Insights From the Excellence in Peripheral Artery Disease (XLPAD) Registry. ( 30611122 )
2019
44
Critical appraisal of international guidelines for the screening and treatment of asymptomatic peripheral artery disease: a systematic review. ( 30646843 )
2019
45
Serum magnesium and the prevalence of peripheral artery disease: The Atherosclerosis Risk in Communities (ARIC) study. ( 30658844 )
2019
46
Racial Differences in the Effect of Granulocyte Macrophage Colony-Stimulating Factor on Improved Walking Distance in Peripheral Artery Disease: The PROPEL Randomized Clinical Trial. ( 30661439 )
2019
47
Peripheral artery disease risk factors in Jeddah, Saudi Arabia: a retrospective study. ( 30662279 )
2019
48
Sex Differences in Outcomes Following Endovascular Treatment for Symptomatic Peripheral Artery Disease: An Analysis From the K- VIS ELLA Registry. ( 30663486 )
2019
49
Guideline-Oriented Therapy of Lower Extremity Peripheral Artery Disease (PAD) - Current Data and Perspectives. ( 30665251 )
2019
50
Radial Artery Tonometry is Associated With Major Adverse Cardiac Events in Patients With Peripheral Artery Disease. ( 30691803 )
2019

Variations for Arteries, Anomalies of

Expression for Arteries, Anomalies of

Search GEO for disease gene expression data for Arteries, Anomalies of.

Pathways for Arteries, Anomalies of

Pathways related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.22 AGTR1 ALB APOA1 APOB APOE COG2
2
Show member pathways
12.86 ACE AGT AGTR1 IL6 INS REN
3
Show member pathways
12.47 ALB APOA1 APOB APOE LPA
4
Show member pathways
12.12 ACE AGT INS REN
5 11.97 EDN1 NOS3 PLAT VCAM1
6 11.9 ALB APOA1 APOE TNNI3
7
Show member pathways
11.85 APOA1 APOB APOE LPA
8 11.78 ALB IL6 INS TNNI3 VCAM1
9
Show member pathways
11.77 ALB APOA1 APOB APOE
10 11.71 EDN1 IL6 INS NOS3
11
Show member pathways
11.61 ALB APOA1 APOB APOE CRP IL6
12 11.55 AGTR1 EDN1 IL6 NOS3 VCAM1
13 11.46 ACE AGT AGTR1 REN
14 11.37 ALB APOA1 INS
15 11.25 APOA1 IL6 VCAM1
16 11.03 APOB IL6 LPA PLAT PLG
17 10.91 ACE PLAT PLG
18 10.69 PLAT PLG

GO Terms for Arteries, Anomalies of

Cellular components related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 early endosome GO:0005769 9.81 APOA1 APOB APOE VCAM1
2 extracellular region GO:0005576 9.8 ACE AGT ALB APOA1 APOB APOE
3 endoplasmic reticulum lumen GO:0005788 9.73 ALB APOA1 APOB APOE IL6 INS
4 blood microparticle GO:0072562 9.72 AGT ALB APOA1 APOE PLG
5 apical part of cell GO:0045177 9.7 PLAT REN VCAM1
6 very-low-density lipoprotein particle GO:0034361 9.63 APOA1 APOB APOE
7 endocytic vesicle lumen GO:0071682 9.61 APOA1 APOB APOE
8 low-density lipoprotein particle GO:0034362 9.58 APOA1 APOB APOE
9 chylomicron GO:0042627 9.54 APOA1 APOB APOE
10 discoidal high-density lipoprotein particle GO:0034365 9.48 APOA1 APOE
11 extracellular space GO:0005615 9.47 ACE AGT ALB APOA1 APOB APOE
12 intermediate-density lipoprotein particle GO:0034363 9.33 APOA1 APOB APOE
13 extracellular exosome GO:0070062 10.15 ACE AGT ALB APOA1 APOB APOE

Biological processes related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

(show top 50) (show all 58)
# Name GO ID Score Top Affiliating Genes
1 receptor-mediated endocytosis GO:0006898 9.99 ALB APOA1 APOB APOE
2 lipid transport GO:0006869 9.94 APOA1 APOB APOE LPA
3 kidney development GO:0001822 9.91 ACE AGT AGTR1 REN
4 cholesterol homeostasis GO:0042632 9.89 APOA1 APOB APOE
5 cholesterol metabolic process GO:0008203 9.89 APOA1 APOB APOE
6 response to lipopolysaccharide GO:0032496 9.89 APOB EDN1 NOS3 REN VCAM1
7 retinoid metabolic process GO:0001523 9.85 APOA1 APOB APOE
8 acute-phase response GO:0006953 9.81 CRP IL6 INS
9 blood vessel remodeling GO:0001974 9.79 ACE AGT NOS3
10 triglyceride catabolic process GO:0019433 9.78 APOA1 APOB APOE
11 cholesterol efflux GO:0033344 9.77 APOA1 APOB APOE
12 lipoprotein metabolic process GO:0042157 9.76 APOA1 APOB APOE
13 vasodilation GO:0042311 9.75 AGT APOE NOS3
14 nitric oxide mediated signal transduction GO:0007263 9.74 AGT APOE NOS3
15 regulation of blood vessel size GO:0050880 9.73 AGT EDN1 NOS3
16 amyloid-beta metabolic process GO:0050435 9.72 ACE REN
17 positive regulation of renal sodium excretion GO:0035815 9.72 AGT EDN1
18 regulation of blood vessel diameter GO:0097746 9.72 ACE AGTR1
19 high-density lipoprotein particle assembly GO:0034380 9.72 APOA1 APOE
20 high-density lipoprotein particle remodeling GO:0034375 9.72 ALB APOA1 APOE
21 phospholipid efflux GO:0033700 9.71 APOA1 APOE
22 angiotensin maturation GO:0002003 9.71 ACE REN
23 artery smooth muscle contraction GO:0014824 9.71 AGT EDN1
24 high-density lipoprotein particle clearance GO:0034384 9.71 APOA1 APOE
25 positive regulation of cellular protein metabolic process GO:0032270 9.71 AGT AGTR1 INS
26 negative regulation of blood vessel diameter GO:0097756 9.7 CRP INS
27 negative regulation of lipid storage GO:0010888 9.7 CRP IL6
28 negative regulation of platelet activation GO:0010544 9.7 APOE NOS3
29 very-low-density lipoprotein particle remodeling GO:0034372 9.7 APOA1 APOE
30 positive regulation of lipid biosynthetic process GO:0046889 9.7 APOA1 APOE INS
31 cellular protein metabolic process GO:0044267 9.7 ALB APOA1 APOB APOE IL6 INS
32 chylomicron remnant clearance GO:0034382 9.69 APOB APOE
33 neutrophil mediated immunity GO:0002446 9.69 ACE IL6
34 positive regulation of macrophage derived foam cell differentiation GO:0010744 9.69 AGT AGTR1 APOB
35 negative regulation of hydrolase activity GO:0051346 9.68 APOA1 NOS3
36 positive regulation of NAD(P)H oxidase activity GO:0033864 9.68 AGT AGTR1
37 regulation of Cdc42 protein signal transduction GO:0032489 9.68 APOA1 APOE
38 regulation of cholesterol transport GO:0032374 9.67 APOA1 APOE
39 negative regulation of cellular protein metabolic process GO:0032269 9.67 APOE EDN1
40 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.66 EDN1 NOS3
41 very-low-density lipoprotein particle clearance GO:0034447 9.66 APOB APOE
42 positive regulation of dendritic spine maintenance GO:1902952 9.65 APOE INS
43 regulation of renal sodium excretion GO:0035813 9.65 AGT AGTR1
44 chylomicron assembly GO:0034378 9.65 APOA1 APOB APOE
45 regulation of blood pressure GO:0008217 9.65 ACE AGT EDN1 NOS3 REN
46 lipoprotein catabolic process GO:0042159 9.63 APOB APOE
47 regulation of blood vessel diameter by renin-angiotensin GO:0002034 9.63 AGT AGTR1
48 chylomicron remodeling GO:0034371 9.63 APOA1 APOB APOE
49 regulation of blood volume by renin-angiotensin GO:0002016 9.62 AGT REN
50 regulation of vasoconstriction GO:0019229 9.62 ACE AGT AGTR1 EDN1

Molecular functions related to Arteries, Anomalies of according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidase activity GO:0008233 9.85 ACE LPA PLAT PLG REN
2 endopeptidase activity GO:0004175 9.61 ACE PLG REN
3 lipid transporter activity GO:0005319 9.43 APOA1 APOB APOE
4 lipoprotein particle binding GO:0071813 9.37 APOA1 APOE
5 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.32 APOA1 APOE
6 bradykinin receptor binding GO:0031711 9.16 ACE AGTR1
7 low-density lipoprotein particle receptor binding GO:0050750 9.13 APOB APOE CRP
8 cholesterol transporter activity GO:0017127 8.8 APOA1 APOB APOE
9 protein binding GO:0005515 10.33 AGT AGTR1 ALB APOA1 APOB APOE

Sources for Arteries, Anomalies of

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....